Miravirsen
- Generic Name
- Miravirsen
- Drug Type
- Biotech
- CAS Number
- 1072874-90-8
- Unique Ingredient Identifier
- Q083AJW7VS
- Background
Miravirsen has been investigated for the treatment of Hepatitis C and Hepatitis C, Chronic.
Miravirsen in Combination With Telaprevir and Ribavirin in Null Responder to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Infection
- First Posted Date
- 2013-06-07
- Last Posted Date
- 2014-11-18
- Lead Sponsor
- Santaris Pharma A/S
- Target Recruit Count
- 20
- Registration Number
- NCT01872936
- Locations
- 🇺🇸
Research Specialists of Texas, Houston, Texas, United States
🇺🇸The Liver Institute at Methodist Dallas Medical Center, Dallas, Texas, United States
🇵🇷Fundacion de Investigacion de Diego, San Juan, Puerto Rico
Miravirsen Study in Null Responder to Pegylated Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C
- First Posted Date
- 2012-11-16
- Last Posted Date
- 2014-01-06
- Lead Sponsor
- Santaris Pharma A/S
- Target Recruit Count
- 10
- Registration Number
- NCT01727934
- Locations
- 🇵🇷
Fundacion de Investigation de Diego, San Juan, Puerto Rico
Drug Interaction Study to Assess the Effect of Co-Administered Miravirsen and Telaprevir in Healthy Subjects
- Conditions
- Hepatitis CChronic Hepatitis C
- Interventions
- First Posted Date
- 2012-07-20
- Last Posted Date
- 2012-11-12
- Lead Sponsor
- Santaris Pharma A/S
- Target Recruit Count
- 5
- Registration Number
- NCT01646489
- Locations
- 🇺🇸
Spaulding Clinical Research, West Bend, Wisconsin, United States
Multiple Ascending Dose Study of Miravirsen in Treatment-Naïve Chronic Hepatitis C Subjects
- First Posted Date
- 2010-09-13
- Last Posted Date
- 2012-01-31
- Lead Sponsor
- Santaris Pharma A/S
- Target Recruit Count
- 38
- Registration Number
- NCT01200420
- Locations
- 🇵🇷
Fundacion de Investigation de Diego, San Juan, Puerto Rico
🇩🇪J.W. Goethe University Hospital, Frankfurt, Germany
🇺🇸Alamo Medical Research, San Antonio, Texas, United States
SPC3649 Multiple Dose Study in Healthy Volunteers
- First Posted Date
- 2009-09-18
- Last Posted Date
- 2011-10-05
- Lead Sponsor
- Santaris Pharma A/S
- Target Recruit Count
- 30
- Registration Number
- NCT00979927
- Locations
- 🇳🇱
PRA international, Zuidlaren, Netherlands
Safety Study of SPC3649 in Healthy Men
- Conditions
- Hepatitis C
- First Posted Date
- 2008-06-02
- Last Posted Date
- 2009-09-18
- Lead Sponsor
- Santaris Pharma A/S
- Target Recruit Count
- 64
- Registration Number
- NCT00688012
- Locations
- 🇩🇰
PhaseOne Trials, Hvidovre University Hospital, Hvidovre, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.